Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Expert Review of Anticancer Therapy
|
April 25, 2022
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
Charlene M Mantia, Guru Sonpavde
The Journal of Urology
|
May 4, 2021
Editorial Comment
Charlene M Mantia, Guru P Sonpavde
Cancer
|
September 19, 2019
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma
Charlene M Mantia, David F McDermott
Hematology/Oncology Clinics of North America
|
March 6, 2019
Immunotherapy Toxicity
Charlene M Mantia, Elizabeth I Buchbinder
Journal of Clinical Medicine
|
February 13, 2025
Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy
Izuagie Ikhapoh, Usomine Atairu, Amanda Jane Reich, et al.
Melanoma Research
|
December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
Charlene M Mantia, Lillian Werner, Brian Stwalley, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
JCO Oncology Practice
|
July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors
Charlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
Anita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Expert Review of Anticancer Therapy
|
April 25, 2022
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma
Charlene M Mantia, Guru Sonpavde
The Journal of Urology
|
May 4, 2021
Editorial Comment
Charlene M Mantia, Guru P Sonpavde
Cancer
|
September 19, 2019
Vascular endothelial growth factor and programmed death-1 pathway inhibitors in renal cell carcinoma
Charlene M Mantia, David F McDermott
Hematology/Oncology Clinics of North America
|
March 6, 2019
Immunotherapy Toxicity
Charlene M Mantia, Elizabeth I Buchbinder
Journal of Clinical Medicine
|
February 13, 2025
Examining Patient Characteristics in Bladder Cancer Clinical Trials Involving Immunotherapy
Izuagie Ikhapoh, Usomine Atairu, Amanda Jane Reich, et al.
Melanoma Research
|
December 2, 2021
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors
Charlene M Mantia, Lillian Werner, Brian Stwalley, et al.
Journal for Immunotherapy of Cancer
|
January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Hollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.
JCO Oncology Practice
|
July 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors
Charlene M Mantia, Opeyemi A Jegede, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2020
Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors
Anita Gul, Tyler F Stewart, Charlene M Mantia, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2021
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067
Meredith M Regan, Charlene M Mantia, Lillian Werner, et al.
Page
of 2